Lantern Pharma (NASDAQ:LTRN) Trading Up 2.3%

Lantern Pharma Inc. (NASDAQ:LTRN) shares shot up 2.3% on Tuesday . The stock traded as high as $4.09 and last traded at $4.04. 30,390 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 151,501 shares. The stock had previously closed at $3.95.

Lantern Pharma Stock Up 2.3 %

The stock has a market capitalization of $43.47 million, a P/E ratio of -2.48 and a beta of 1.56. The stock’s 50 day moving average price is $4.11 and its 200-day moving average price is $5.50.

Lantern Pharma (NASDAQ:LTRN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.09. During the same period last year, the firm earned ($0.44) earnings per share. Analysts anticipate that Lantern Pharma Inc. will post -2.12 earnings per share for the current year.

Institutional Trading of Lantern Pharma

Several large investors have recently made changes to their positions in LTRN. Renaissance Technologies LLC raised its holdings in Lantern Pharma by 24.5% in the 2nd quarter. Renaissance Technologies LLC now owns 81,800 shares of the company’s stock valued at $382,000 after acquiring an additional 16,100 shares during the last quarter. CM Management LLC lifted its stake in Lantern Pharma by 23.1% during the second quarter. CM Management LLC now owns 80,000 shares of the company’s stock worth $374,000 after purchasing an additional 15,000 shares in the last quarter. Tocqueville Asset Management L.P. purchased a new position in shares of Lantern Pharma during the first quarter worth $167,000. Dimensional Fund Advisors LP grew its stake in shares of Lantern Pharma by 55.7% in the second quarter. Dimensional Fund Advisors LP now owns 18,413 shares of the company’s stock valued at $86,000 after buying an additional 6,585 shares in the last quarter. Finally, Westside Investment Management Inc. purchased a new stake in shares of Lantern Pharma in the 2nd quarter valued at $54,000. 28.62% of the stock is currently owned by hedge funds and other institutional investors.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.